Ainos Responds to FDA for Phase II Trial of VELDONA for Mild COVID-19

Anos, Inc., a leading healthcare enterprise, has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) to address a clinical hold for its Phase II trial of VELDONA®, a low-dose oral interferon therapy for mild COVID-19 symptoms. The company is poised to conduct a multicenter, randomized study in Taiwan during the third quarter of 2024, pending approval.
Eddy Tsai, CEO of Anos, expressed optimism about the company's ability to address the FDA's concerns and the potential of VELDONA® to become a significant treatment for mild COVID-19 symptoms. The manufacturing process for VELDONA® adheres to stringent regulatory standards, ensuring product stability and quality. Anos is also planning additional IND applications for VELDONA® in treating oral warts in HIV-positive patients and Sjögren's syndrome.
The company's commitment to innovation is evident in its development of VELDONA®, which aims to enhance immune responses against viral infections with reduced side effects compared to traditional treatments. Anos has a track record of successful clinical trials with low-dose oral interferon, involving nearly 6,000 participants across various conditions.
Anos, headquartered in San Diego, is dedicated to advancing novel healthcare solutions, including point-of-care testing and synthetic RNA-based preventative medicine. The company's product lineup includes VELDONA® therapeutics for humans and pets, as well as AI-driven telehealth-compatible point-of-care tests.